About: Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.00 (-11.11%)
RAD ASX Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd share price
RAD price activity
Last Price
$0.000
Change (24hr)
-0.00 AUD (11.11%)
Volume
74.36K
Volume (4w avg)
-
Open
$0.00
Day Range
$0.00 - $0.00
Previous Close
$0.00
Last Trade
29 Oct, 2:44 am GMT+0
Delayed
29 Oct, 2:44 am GMT+0
RAD price performance
Delayed
29 Oct, 2:44 am GMT+0
RAD Market Signals